Gerresheimer Expands Financial Flexibility To Implement Growth Strategy

EQS-News: Gerresheimer AG / Key word(s): Financing
Gerresheimer expands financial flexibility to implement growth strategy
28.08.2025 / 09:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

Gerresheimer expands financial flexibility to implement growth strategy

• Loans of EUR 200 million to repay part of the bridge financing for the acquisition of Bormioli Pharma ahead of schedule
• Expansion of flexibility in key contractual terms

Duesseldorf, August 28, 2025. Gerresheimer, an innovative system and solution provider and global partner to the pharma, biotech, and cosmetics industries, will prematurely repay part of the bridge financing for the acquisition of Bormioli Pharma with two loans totaling EUR 200 million from BayernLB and Landesbank Hessen-Thüringen. At the same time, certain key terms of the existing revolving credit facility of EUR 675 million and the remaining bridge financing of around EUR 525 million have been adjusted to provide greater flexibility. Gerresheimer has thus optimized the maturity profile of its corporate financing and increased its flexibility to implement its growth strategy as planned.

“Our corporate financing is solid, predictable in the long term, and flexible,” said Dietmar Siemssen, CEO of Gerresheimer AG.“We have the necessary financial headroom to continue driving forward our strategy with selective growth investments and a focus on free cash flow as planned.”

Optimized maturity profile of corporate financing

With the two loans of EUR 100 million each at market terms from BayernLB and Landesbank Hessen-Thüringen, Gerresheimer is replacing part of the bridge financing concluded in fall 2024 for the acquisition of the Bormioli Pharma Group. The company had already extended the bridge financing until September 2027 in May 2025. The optimized maturity profile and more flexible terms give Gerresheimer room for maneuver in its next strategic steps.

Financial headroom for implementing the corporate strategy

Gerresheimer will continue to invest selectively in margin-enhancing growth projects as part of its corporate strategy and is aiming for positive free cash flow in 2026.

About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,600 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).

Contact Gerresheimer AG

28.08.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at